Invention Grant
- Patent Title: Method of treating a tumor necrosis factor α (TNFα)-related disorder by using an induction dosing regimen of adalimumab
-
Application No.: US16014446Application Date: 2018-06-21
-
Publication No.: US10669333B2Publication Date: 2020-06-02
- Inventor: Rachel Moodie , Elizabeth Hyland
- Applicant: Fresenius Kabi Deutschland GmbH
- Applicant Address: DE Bad Homburg
- Assignee: Fresenius Kabi Deutschland GmbH
- Current Assignee: Fresenius Kabi Deutschland GmbH
- Current Assignee Address: DE Bad Homburg
- Agency: Goodwin Procter LLP
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@2f791809 com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@70f8f831
- Main IPC: A61K39/00
- IPC: A61K39/00 ; C07K16/24
Abstract:
The invention relates to a multiple-variable dose method for treating a disorder in which TNFα activity is detrimental, comprising administering to a subject in need thereof a first induction dose of an anti-TNFα antibody which ranges from 161 to 320 mg such that a threshold level of TNFα inhibitor is achieved within an induction phase; and subsequently administering to the subject at least one treatment dose of the TNFα inhibitor within a treatment phase, such that treatment occurs.
Public/Granted literature
- US20180291091A1 INDUCTION DOSING REGIMEN Public/Granted day:2018-10-11
Information query
